Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
281
-
282
-
283
C2GnT1 gene knockdown decreases C2-O-sLe<sup>X</sup> glycoproteins and C2GnT1 activity.
Published 2013“…Note the absence of a detected C2GnT1 protein 50 kDa band. (D) We observed a 30–40% decrease in reactivity with CHO-131 mAb by flow cytometry for LS174T and HepG2 cells that contained C2GnT1 shRNA. …”
-
284
-
285
-
286
Data_Sheet_1_Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflamatory Reaction.PDF
Published 2021“…Mean sC2C levels (220.83 ± 39.50 ng/ml) decreased post-race (188.67 ± 38.52 ng/ml) (p = 0.002). …”
-
287
-
288
-
289
-
290
-
291
-
292
-
293
-
294
Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo.
Published 2013“…The proportion of ALDH+ cells is expressed as mean ± SEM (n = 2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 µM (p = 0.0060), 25 µM (p = 0,0013) and 50 µM galiellalactone (p<0,0001). …”
-
295
-
296
-
297
-
298
-
299
DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx
Published 2022“…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”
-
300